Back to top

gene-editing: Archive

Zacks Equity Research

CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?

CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.

VRTXPositive Net Change MRNAPositive Net Change CRSPPositive Net Change CSTLPositive Net Change